Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.

Shah A, Bloomquist E, Tang S, Fu W, Bi Y, Liu Q, Yu J, Zhao P, Palmby TR, Goldberg KB, Chang CJG, Patel P, Alebachew E, Tilley A, Pierce WF, Ibrahim A, Blumenthal GM, Sridhara R, Beaver JA, Pazdur R.

Clin Cancer Res. 2018 Feb 7. pii: clincanres.2369.2017. doi: 10.1158/1078-0432.CCR-17-2369. [Epub ahead of print]

PMID:
29437768
2.

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer.

Balasubramaniam S, Beaver JA, Horton S, Fernandes LL, Tang S, Horne HN, Liu J, Liu C, Schrieber SJ, Yu J, Song P, Pierce W, Robertson KJ, Palmby TR, Chiu HJ, Lee EY, Philip R, Schuck R, Charlab R, Banerjee A, Chen XH, Wang X, Goldberg KB, Sridhara R, Kim G, Pazdur R.

Clin Cancer Res. 2017 Dec 1;23(23):7165-7170. doi: 10.1158/1078-0432.CCR-17-1337. Epub 2017 Jul 27.

PMID:
28751443
3.

U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma.

Singh H, Brave M, Beaver JA, Cheng J, Tang S, Zahalka E, Palmby TR, Venugopal R, Song P, Liu Q, Liu C, Yu J, Chen XH, Wang X, Wang Y, Kluetz PG, Daniels SR, Papadopoulos EJ, Sridhara R, McKee AE, Ibrahim A, Kim G, Pazdur R.

Clin Cancer Res. 2017 Jan 15;23(2):330-335. doi: 10.1158/1078-0432.CCR-16-1073. Epub 2016 Oct 28.

4.

FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.

Walker AJ, Wedam S, Amiri-Kordestani L, Bloomquist E, Tang S, Sridhara R, Chen W, Palmby TR, Fourie Zirkelbach J, Fu W, Liu Q, Tilley A, Kim G, Kluetz PG, McKee AE, Pazdur R.

Clin Cancer Res. 2016 Oct 15;22(20):4968-4972. Epub 2016 Jul 12.

5.

FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs.

Ison G, Beaver JA, McGuinn WD Jr, Palmby TR, Dinin J, Charlab R, Marathe A, Jin R, Liu Q, Chen XH, Ysern X, Stephens O, Bai G, Wang Y, Dorff SE, Cheng J, Tang S, Sridhara R, Pierce W, McKee AE, Ibrahim A, Kim G, Pazdur R.

Clin Cancer Res. 2016 Sep 15;22(18):4545-9. doi: 10.1158/1078-0432.CCR-16-0638. Epub 2016 Jul 11. Review.

6.

Nonclinical Evaluations of Small-Molecule Oncology Drugs: Integration into Clinical Dose Optimization and Toxicity Management.

Dambach DM, Simpson NE, Jones TW, Brennan RJ, Pazdur R, Palmby TR.

Clin Cancer Res. 2016 Jun 1;22(11):2618-22. doi: 10.1158/1078-0432.CCR-15-2645.

7.

U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.

Herndon TM, Deisseroth A, Kaminskas E, Kane RC, Koti KM, Rothmann MD, Habtemariam B, Bullock J, Bray JD, Hawes J, Palmby TR, Jee J, Adams W, Mahayni H, Brown J, Dorantes A, Sridhara R, Farrell AT, Pazdur R.

Clin Cancer Res. 2013 Sep 1;19(17):4559-63. doi: 10.1158/1078-0432.CCR-13-0755. Epub 2013 Jun 17.

8.

PDZ-RhoGEF and LARG are essential for embryonic development and provide a link between thrombin and LPA receptors and Rho activation.

Mikelis CM, Palmby TR, Simaan M, Li W, Szabo R, Lyons R, Martin D, Yagi H, Fukuhara S, Chikumi H, Galisteo R, Mukouyama YS, Bugge TH, Gutkind JS.

J Biol Chem. 2013 Apr 26;288(17):12232-43. doi: 10.1074/jbc.M112.428599. Epub 2013 Mar 6.

9.

Semaphorin 3E initiates antiangiogenic signaling through plexin D1 by regulating Arf6 and R-Ras.

Sakurai A, Gavard J, Annas-Linhares Y, Basile JR, Amornphimoltham P, Palmby TR, Yagi H, Zhang F, Randazzo PA, Li X, Weigert R, Gutkind JS.

Mol Cell Biol. 2010 Jun;30(12):3086-98. doi: 10.1128/MCB.01652-09. Epub 2010 Apr 12.

10.

An essential role for Rac1 in endothelial cell function and vascular development.

Tan W, Palmby TR, Gavard J, Amornphimoltham P, Zheng Y, Gutkind JS.

FASEB J. 2008 Jun;22(6):1829-38. doi: 10.1096/fj.07-096438. Epub 2008 Feb 1.

PMID:
18245172
11.

Multiple PPPS/TP motifs act in a combinatorial fashion to transduce Wnt signaling through LRP6.

Wolf J, Palmby TR, Gavard J, Williams BO, Gutkind JS.

FEBS Lett. 2008 Jan 23;582(2):255-61. Epub 2007 Dec 18.

12.

Vav transformation requires activation of multiple GTPases and regulation of gene expression.

Palmby TR, Abe K, Karnoub AE, Der CJ.

Mol Cancer Res. 2004 Dec;2(12):702-11.

13.

Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation.

Singh A, Karnoub AE, Palmby TR, Lengyel E, Sondek J, Der CJ.

Oncogene. 2004 Dec 16;23(58):9369-80.

PMID:
15516977
14.

Critical role of the pleckstrin homology and cysteine-rich domains in Vav signaling and transforming activity.

Palmby TR, Abe K, Der CJ.

J Biol Chem. 2002 Oct 18;277(42):39350-9. Epub 2002 Aug 12.

Supplemental Content

Loading ...
Support Center